Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Beats Rivals To Japan HIF-PHI Market As Roxadustat Launched

Executive Summary

Astellas becomes first to market in Japan in new class of oral anemia drugs, beating multiple rivals in a sector set to see strong growth but also fierce competition.

You may also be interested in...



Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

Vadadustat Emerges As Japan HIF-PHI Contender With First Filing Globally

Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.

First Approval For AZ's Roxadustat With China Green Light

China is the first country to give the green light to roxadustat, AstraZeneca and FibroGen's first-in-class oral inhibitor of HIF-PHI, which could become standard of care to treat anemia in chronic kidney disease patients.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141212

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel